293 related articles for article (PubMed ID: 33782686)
1. The landscape and prognostic value of immune characteristics in uterine corpus endometrial cancer.
Liu W; Sun L; Zhang J; Song W; Li M; Wang H
Biosci Rep; 2021 Apr; 41(4):. PubMed ID: 33782686
[TBL] [Abstract][Full Text] [Related]
2. Development and Clinical Validation of Novel 8-Gene Prognostic Signature Associated With the Proportion of Regulatory T Cells by Weighted Gene Co-Expression Network Analysis in Uterine Corpus Endometrial Carcinoma.
Liu J; Geng R; Yang S; Shao F; Zhong Z; Yang M; Ni S; Cai L; Bai J
Front Immunol; 2021; 12():788431. PubMed ID: 34970268
[TBL] [Abstract][Full Text] [Related]
3. KDM4B, a potential prognostic biomarker revealed by large-scale public databases and clinical samples in uterine corpus endometrial carcinoma.
Zhang M; Liu Y; Hou S; Wang Y; Wang C; Yin Y; Chen X
Mol Omics; 2022 Jul; 18(6):506-519. PubMed ID: 35485290
[TBL] [Abstract][Full Text] [Related]
4. Integrated analysis of tumor mutation burden and immune infiltrates in endometrial cancer.
Zhou H; Chen L; Lei Y; Li T; Li H; Cheng X
Curr Probl Cancer; 2021 Apr; 45(2):100660. PubMed ID: 33012523
[TBL] [Abstract][Full Text] [Related]
5. Construction of N-7 methylguanine-related mRNA prognostic model in uterine corpus endometrial carcinoma based on multi-omics data and immune-related analysis.
Zhao J; Zou J; Jiao W; Lin L; Wang J; Lin Z
Sci Rep; 2022 Nov; 12(1):18813. PubMed ID: 36335189
[TBL] [Abstract][Full Text] [Related]
6. PTEN mutation: A potential prognostic factor associated with immune infiltration in endometrial carcinoma.
Tao Y; Liang B
Pathol Res Pract; 2020 Jun; 216(6):152943. PubMed ID: 32279917
[TBL] [Abstract][Full Text] [Related]
7. Identification of an endoplasmic reticulum stress-related gene signature to predict prognosis and potential drugs of uterine corpus endometrial cancer.
Zhou P; Wu C; Ma C; Luo T; Yuan J; Zhou P; Wei Z
Math Biosci Eng; 2023 Jan; 20(2):4018-4039. PubMed ID: 36899615
[TBL] [Abstract][Full Text] [Related]
8. Pan-Cancer Gene Analysis of m6A Modification and Immune Infiltration in Uterine Corpus Endometrial Carcinoma.
Xie BF; Xia Y; Lin DH; Lian B; Zhang ML; Liu L; Qin CR
Comput Intell Neurosci; 2022; 2022():6530884. PubMed ID: 36199963
[TBL] [Abstract][Full Text] [Related]
9. Identification of prognostic and immune-related gene signatures in the tumor microenvironment of endometrial cancer.
Wang G; Wang D; Sun M; Liu X; Yang Q
Int Immunopharmacol; 2020 Nov; 88():106931. PubMed ID: 32889237
[TBL] [Abstract][Full Text] [Related]
10. FAT2 mutation is associated with better prognosis and responsiveness to immunotherapy in uterine corpus endometrial carcinoma.
Wang Z; Xing L; Huang Y; Han P
Cancer Med; 2023 Feb; 12(3):3797-3811. PubMed ID: 36812126
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive Analysis of ESRRA in Endometrial Cancer.
Wang S; Huo X
Technol Cancer Res Treat; 2021; 20():1533033821992083. PubMed ID: 33525981
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of novel immune-related genomic biomarkers identified in head and neck squamous cell carcinoma.
Yao Y; Yan Z; Lian S; Wei L; Zhou C; Feng D; Zhang Y; Yang J; Li M; Chen Y
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32719094
[TBL] [Abstract][Full Text] [Related]
13. A novel alternative splicing-based prediction model for uteri corpus endometrial carcinoma.
Gao L; Xie ZC; Pang JS; Li TT; Chen G
Aging (Albany NY); 2019 Jan; 11(1):263-283. PubMed ID: 30640723
[TBL] [Abstract][Full Text] [Related]
14. Identification of an Immune-Related LncRNA Prognostic Signature in Uterine Corpus Endometrial Carcinoma Patients.
Sun XX; Wen HQ; Zhan BX; Yang P
Clin Lab; 2021 Nov; 67(11):. PubMed ID: 34758230
[TBL] [Abstract][Full Text] [Related]
15. Construction of a microenvironment immune gene model for predicting the prognosis of endometrial cancer.
Wang Y; Zhang J; Zhou Y; Li Z; Lv D; Liu Q
BMC Cancer; 2021 Nov; 21(1):1203. PubMed ID: 34763648
[TBL] [Abstract][Full Text] [Related]
16. Identification of a six-gene signature with prognostic value for patients with endometrial carcinoma.
Wang Y; Ren F; Chen P; Liu S; Song Z; Ma X
Cancer Med; 2018 Nov; 7(11):5632-5642. PubMed ID: 30306731
[TBL] [Abstract][Full Text] [Related]
17. LINC01589 serves as a potential tumor-suppressor and immune-related biomarker in endometrial cancer: A review.
Chen R; An J; Wang Y; Yang L; Lin Q; Wang Y
Medicine (Baltimore); 2023 Apr; 102(15):e33536. PubMed ID: 37058060
[TBL] [Abstract][Full Text] [Related]
18. Identification and Validation of Cuproptosis-Related Prognostic Signature and Associated Regulatory Axis in Uterine Corpus Endometrial Carcinoma.
Chen Y
Front Genet; 2022; 13():912037. PubMed ID: 35937995
[No Abstract] [Full Text] [Related]
19. Relationship between Prognosis, Immune Infiltration Level, and Differential Expression of PARVG Gene in Uterine Corpus Endometrial Carcinoma.
Wang F; Bi J; Yi C; Zhang Y; Zhang Y; Yue Q
Contrast Media Mol Imaging; 2022; 2022():7376588. PubMed ID: 35655721
[TBL] [Abstract][Full Text] [Related]
20. Glycosyltransferase-related prognostic and diagnostic biomarkers of uterine corpus endometrial carcinoma.
Wu J; Zhou X; Ren J; Zhang Z; Ju H; Diao X; Jiang S; Zhang J
Comput Biol Med; 2023 Sep; 163():107164. PubMed ID: 37329616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
